Medicenna Therapeutics Corp. Common Shares
MDNA
MDNA was delisted on the 1st of November, 2023.
27 hedge funds and large institutions have $4.15M invested in Medicenna Therapeutics Corp. Common Shares in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 27 → 27 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
26% less capital invested
Capital invested by funds: $5.6M → $4.15M (-$1.45M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$33.2K |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
+$21.7K |
| 3 |
VF
Virtu Financial
New York
|
+$13.3K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$2.01K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$1.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$44K |
| 2 |
Renaissance Technologies
New York
|
-$37K |
| 3 |
LBA
Letko, Brosseau & Associates
Montreal,
Quebec, Canada
|
-$30.9K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$26.9K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$8.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
National Bank of Canada
Montreal,
Quebec, Canada
| $272 | +$371 | +600 | New |
|
|
27
Millennium Management
New York
| – | -$44K | -68,215 | Closed |
|
|
BAM
28
Belpointe Asset Management
Reno,
Nevada
| – | -$6.45K | -10,249 | Closed |
|
|
ASN
29
Advisory Services Network
Atlanta,
Georgia
| – | -$470 | -747 | Closed |
|
30
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$33 | +54 | +11% |
|
MDNA Hedge Fund Activity: Q2 2023 in Review
27 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Medicenna Therapeutics Corp. Common Shares (MDNA) for Q2 2023, worth a combined $4.15M — down 26% from $5.6M a quarter earlier.
Fund positioning in MDNA was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $33.2K. The largest seller was Millennium Management, exiting entirely with an estimated $44K sold.
- 27 institutional investors held Medicenna Therapeutics Corp. Common Shares (MDNA) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $4.15M of Medicenna Therapeutics Corp. Common Shares stock for Q2 2023, down 26% quarter-over-quarter.
- 3 funds opened new Medicenna Therapeutics Corp. Common Shares positions in Q2 2023 and 3 closed out, a net change of 0 holders.
- The largest Medicenna Therapeutics Corp. Common Shares buyer in Q2 2023 was Susquehanna International Group, an estimated $33.2K added.
- The largest Medicenna Therapeutics Corp. Common Shares seller in Q2 2023 was Millennium Management, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2023.